Navigation Links
MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
Date:10/4/2007

diatric patients and met a secondary endpoint of reducing medically attended, outpatient respiratory tract infections in that patient group. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab, formerly known as Numax(R), is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis (palivizumab) in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its first pivotal trial, which was a head-to-head comparative trial with Synagis (palivizumab), motavizumab met its non-inferiority objective by demonstrating a 26-percent relative reduction in RSV hospitalizations and also showed a statistically significant 50-perce
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... N.J., April 28, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... presented at the European League Against Rheumatism (EULAR) 2011 Annual ... 28 in London, United Kingdom, and will feature the abstracts ... The first scheduled oral presentation and the poster session will ...
... April 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ... Healthcare Conference being held May 2 to 4, 2011 at ... America Merrill Lynch Healthcare Conference being held May 10 to ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3
(Date:9/19/2014)... disease, is caused by the bacterium Mycobacterium ... is a legal obligation to report the disease. ... and wasting among affected animals. The disease can ... animals produce less milk, exhibit fertility problems and ... udder inflammation. , To date there has ...
(Date:9/19/2014)... Lifeinsuranceprices.info has released a new blog ... insurance quotes online. , Clients who smoke or ... life insurance quotes from multiple providers on a single ... , Smoking will always influence life insurance prices, ... 50% more for life coverage and if they have ...
(Date:9/19/2014)... The Canton Group, Baltimore’s leading web development ... for the Xaverian Brothers. The new site aligns the Catholic ... edify one another through a life of Gospel witness lived ... manifest God’s care and compassionate love to the people of ... using a responsive web design, which allows users to easily ...
(Date:9/19/2014)... September 19, 2014 2014 Market ... a professional and in-depth research report on Kinesio ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:9/19/2014)... Outsourcing services provider Profit By RPO has ... conglomerate to provide HR outsourcing services in India. , " ... partner and will act as a talent acquisition and transformation ... 120 personnel across 3 locations in India in the next ... is a significant win for us and we are delighted ...
Breaking Medicine News(10 mins):Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:Smokers Can Compare Term Life Insurance Quotes At Lifeinsuranceprices.info! 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 3Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2
... Year, LIVINGSTON, N.J., Dec. 7 MM2 ... its wholly-owned subsidiary,Genotec Nutritionals, Inc., a New York ... distribution of its branded products and,through custom formulations ... strategic venture to manufacture sofgel capsules in Zhongsan,City, ...
... heart disease, ... Gary Stanton., MELBOURNE, Fla., Dec. 7 Heart Savior, (http://www.heartsavior.com ... one Natural product. Lowering unhealthy cholesterol levels is a good,start, but ... in the arteries and the heart muscle itself. The formulators of,Heart ...
... Conn., Dec. 7 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ... (PNH), as well as to Soliris(R),(eculizumab), a treatment for ... Society of Hematology Meeting, December 8 - 11 in ... a poster session on red,cell regulation and disorders of ...
... Dec. 6 Inverness Medical,Innovations, Inc. (Amex: ... rapid,diagnostic products for the consumer and professional markets, ... RBC Capital Markets Healthcare,Conference being held December 12, ... Ron Zwanziger, Chief Executive Officer, and Jon Russell, ...
... Effort is part of the ,Holidays at Mariners Inn - ... Friday, December 7, 2007 at 5:30 p.m. ,These men ... Dec. 6 Homeless men from the,Mariners Inn shelter and ... needy families this holiday season. The men will kick off,their ...
... The American Dietetic,Association welcomes and supports changes announced ... to the nation,s Special Supplemental,Nutrition Program for Women, ... the foods included in the WIC program more ... young children., "These changes are the most ...
Cached Medicine News:Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 2Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 3Health News:New Health Corp. Introduces Heart Savior(TM), the Ultimate Natural Heart Health Product 2Health News:Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting 2Health News:Inverness Medical Innovations to Participate at 2007 RBC Healthcare Conference on December 12, 2007 2Health News:Detroit Homeless Men Adopt Local Families for Christmas 2Health News:American Dietetic Association Supports USDA's New WIC Food Packages 2
Malaria Pf. Assay Range...
An immunochromatographic rapid test for the detection of Plasmodium falciparum in whole blood....
... Uni-Gold™ Pf Malaria Test is a ... presence of Plasmodium falciparum ... an antigen-capture assay detecting presence of ... protein II (PfHRP- II), which is ...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: